Table 1. Association between clinicopathologic characteristics and SMYD2 expression.
| |
SMYD2 immunoreactivity |
|
||
|---|---|---|---|---|
| n | High expression | Low expression | P-valuea | |
| Total |
147 |
56 |
91 |
|
|
Sex | ||||
| Male | 100 | 41 (73%) | 59 (65%) | |
| Female |
47 |
15 (27%) |
32 (35%) |
0.2901 |
|
Age (years) | ||||
| Mean | 63 (range:27–89) | |||
| <60 | 56 | 23 (41%) | 33 (36%) | |
| ⩾60 |
91 |
33 (59%) |
58 (64%) |
0.5036 |
|
Location | ||||
| Upper | 20 | 10 (18%) | 10 (11%) | |
| Middle | 75 | 23 (41%) | 52 (57%) | |
| Lower |
52 |
23 (41%) |
29 (32%) |
0.1505 |
|
Histopathological grading | ||||
| Differentiated | 73 | 32 (57%) | 41 (45%) | |
| Undifferentiated |
74 |
24 (43%) |
50 (55%) |
0.1546 |
|
Tumor size (mm) | ||||
| <40 | 84 | 26 (46%) | 58 (64%) | |
| ⩾40 |
63 |
30 (54%) |
33 (36%) |
0.0394 |
|
Venous invasion | ||||
| 0 | 104 | 35 (63%) | 69 (76%) | |
| 1–3 |
43 |
21 (38%) |
22 (24%) |
0.0846 |
|
Lymphatic invasion | ||||
| 0 | 80 | 20 (36%) | 60 (66%) | |
| 1–3 |
67 |
36 (64%) |
31 (34%) |
0.0003 |
|
TNM classification | ||||
| pT categories | ||||
| pT1 | 83 | 24 (43%) | 59 (65%) | |
| pT2/3 | 34 | 16 (29%) | 18 (20%) | |
| pT4 |
30 |
16 (29%) |
14 (15%) |
0.0290 |
| pN categories | ||||
| N0 | 96 | 34 (61%) | 62 (68%) | |
| N1/2 | 28 | 7 (13%) | 21 (23%) | |
| N3 |
23 |
15 (27%) |
8 (9%) |
0.0204 |
| pStage | ||||
| I | 94 | 31 (55%) | 63 (69%) | |
| II | 16 | 6 (11%) | 10 (11%) | |
| III |
37 |
19 (34%) |
18 (20%) |
0.2117 |
| Rucurrence | ||||
| Absent | 117 | 39 (70%) | 78 (86%) | |
| Present | 30 | 17 (30%) | 13 (14%) | 0.0188 |
Abbreviations: SMYD2=SET and MYND domain-containing protein 2; TNM=tumour-lymph node-metastases.
Statistically significant values are in bold.
a
P-values are from χ2- or Fisher's exact test and were statistically significant at <0.05.